MiR-25 also promotes apoptosis resistance in cholangiocarcinoma by targeting TRAL death receptor-4 [7], as well as ovarian cancer proliferation and motility by targeting LATS2 [8]. This evidence concerns the gene LATS2 and cholangiocarcinoma.